JP2012515210A - ベンダムスチン遊離塩基の新規の形態 - Google Patents

ベンダムスチン遊離塩基の新規の形態 Download PDF

Info

Publication number
JP2012515210A
JP2012515210A JP2011546322A JP2011546322A JP2012515210A JP 2012515210 A JP2012515210 A JP 2012515210A JP 2011546322 A JP2011546322 A JP 2011546322A JP 2011546322 A JP2011546322 A JP 2011546322A JP 2012515210 A JP2012515210 A JP 2012515210A
Authority
JP
Japan
Prior art keywords
free base
bendamustine free
bendamustine
diffraction pattern
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011546322A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012515210A5 (https=
Inventor
コルボアジェ、ローレント、ディー．
エドレストン、マーク
ハルティワンガー、カーティス、アール．
マッキーン、ロバート、イー．
Original Assignee
セファロン、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42008533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2012515210(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セファロン、インク． filed Critical セファロン、インク．
Publication of JP2012515210A publication Critical patent/JP2012515210A/ja
Publication of JP2012515210A5 publication Critical patent/JP2012515210A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP2011546322A 2009-01-15 2010-01-14 ベンダムスチン遊離塩基の新規の形態 Pending JP2012515210A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14484309P 2009-01-15 2009-01-15
US61/144,843 2009-01-15
PCT/US2010/020992 WO2010083276A1 (en) 2009-01-15 2010-01-14 Novel forms of bendamustine free base

Publications (2)

Publication Number Publication Date
JP2012515210A true JP2012515210A (ja) 2012-07-05
JP2012515210A5 JP2012515210A5 (https=) 2013-02-28

Family

ID=42008533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011546322A Pending JP2012515210A (ja) 2009-01-15 2010-01-14 ベンダムスチン遊離塩基の新規の形態

Country Status (16)

Country Link
US (1) US8076366B2 (https=)
EP (1) EP2387400A1 (https=)
JP (1) JP2012515210A (https=)
KR (1) KR20110110293A (https=)
CN (2) CN102281877B (https=)
AU (2) AU2010204765A1 (https=)
BR (1) BRPI1004922A2 (https=)
CA (1) CA2749101A1 (https=)
EA (1) EA020767B1 (https=)
IL (1) IL213725A0 (https=)
MX (1) MX2011007557A (https=)
NZ (1) NZ594010A (https=)
SG (1) SG172810A1 (https=)
UA (1) UA109109C2 (https=)
WO (1) WO2010083276A1 (https=)
ZA (1) ZA201105099B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512529A (ja) * 2013-03-12 2016-04-28 セファロン、インク． ナノ粒子及びナノ粒子製剤

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516404A4 (en) * 2009-12-23 2013-04-17 Reddys Lab Ltd Dr PREPARATION OF BENDAMUSTINE AND ITS SALTS
PL3158991T3 (pl) 2010-01-28 2021-09-27 Eagle Pharmaceuticals, Inc. Preparaty bendamustyny
US9273010B2 (en) * 2011-06-20 2016-03-01 Hetero Research Foundation Process for bendamustine hydrochloride
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
PL2827863T3 (pl) 2012-03-20 2019-07-31 Eagle Pharmaceuticals, Inc. Ciekła kompozycja do zastosowania w sposobie leczenia stanów reagujących na bendamustynę u pacjentów wymagających obniżonych objętości do podawania
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US9629538B2 (en) 2013-04-26 2017-04-25 Vital Art And Science, Llc Contour integration perimetry vision test
US20240148696A1 (en) 2022-10-25 2024-05-09 Softkemo Pharma Inc. Lyophilized bendamustine-cyclodextrin composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80967C (https=)
DE159877C (https=)
DE293808C (https=)
DD159289A1 (de) 1981-06-01 1983-03-02 Uwe Olthoff Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen
US5204335A (en) * 1986-10-31 1993-04-20 Asta Pharma Aktiengesellschaft Ifosfamide lyophilisate and process for its preparation
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5741523A (en) * 1993-10-27 1998-04-21 Pharmacia & Upjohn Company Stabilized prostaglandin E1
US5561121A (en) 1993-11-09 1996-10-01 American Cyanamid Company Stable lyophilized thiotepa composition
US5955504A (en) 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
DE69929440T2 (de) * 1998-07-09 2006-08-17 Cephalon, Inc. Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
US5972912A (en) * 1998-12-17 1999-10-26 S.P. Pharmaceuticals Method for lyophilizing ifosfamide
US6569402B1 (en) * 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6380210B1 (en) * 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6545034B1 (en) * 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
DE10016077A1 (de) 2000-03-31 2001-12-13 Cellcontrol Biomedical Lab Gmb Verfahren und Vorrichtung zum automatischen Nachweisen einer Wirkung eines zellbeeinflussenden Mittels auf lebende Zellen
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
WO2002048142A1 (en) * 2000-12-11 2002-06-20 Takeda Chemical Industries, Ltd. Medicinal compositions having improved absorbability
CA2431319A1 (en) * 2000-12-11 2002-06-20 Hiroto Bando Pharmaceutical composition having an improved water solubility
KR100679990B1 (ko) * 2001-10-15 2007-02-08 헤모텍 게엠베하 재협착증의 방지를 위한 스텐트의 코팅
US6613927B1 (en) * 2002-02-08 2003-09-02 American Pharmaceutical Partners, Inc. Sterile lyophilized ifosfamide and associated methods
DE10306724A1 (de) 2002-02-28 2003-09-18 G O T Therapeutics Gmbh Vesikuläre Verkapselung von Bendamustin
EP1485720B1 (en) 2002-03-22 2008-03-12 Ludwig Maximilians Universität Cytocapacity test
EP1354952A1 (en) 2002-04-17 2003-10-22 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
EP1495124A2 (en) 2002-04-17 2005-01-12 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Smac-peptides as therapeutics against cancer and autoimmune diseases
DE10393059D2 (de) * 2002-05-09 2005-05-04 Hemoteq Gmbh Verbindungen und Verfahren zur hemokompatiblen Beschichtung von Oberflächen
AU2003258061A1 (en) * 2002-08-02 2004-02-23 Salmedix, Inc. Therapeutic inhibitionof protein kinases in cancer cells
DE10304403A1 (de) 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
CA2516191A1 (en) * 2003-02-14 2004-09-02 Salmedix, Inc Compositions and methods for the detection and treatment of methylthioadenosine phosphorylase deficient cancers
CN1829514A (zh) * 2003-07-25 2006-09-06 惠氏公司 Cci－779冻干制剂
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2346836B1 (en) * 2008-10-08 2018-03-07 Cephalon, Inc. Processes for the preparation of bendamustine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD159877A1 (de) * 1981-06-12 1983-04-13 Wolfgang Krueger Verfahren zur herstellung von 4-[1-methyl-5-bis(2-chloraethyl)amino-benzimidazolyl-2]-buttersaeure

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016512529A (ja) * 2013-03-12 2016-04-28 セファロン、インク． ナノ粒子及びナノ粒子製剤

Also Published As

Publication number Publication date
KR20110110293A (ko) 2011-10-06
MX2011007557A (es) 2011-08-12
AU2016204902A1 (en) 2016-08-04
WO2010083276A1 (en) 2010-07-22
BRPI1004922A2 (pt) 2019-09-24
NZ594010A (en) 2013-08-30
UA109109C2 (uk) 2015-07-27
ZA201105099B (en) 2012-03-28
AU2010204765A1 (en) 2011-07-28
US8076366B2 (en) 2011-12-13
EA020767B1 (ru) 2015-01-30
EA201170934A1 (ru) 2011-12-30
US20100210701A1 (en) 2010-08-19
SG172810A1 (en) 2011-08-29
IL213725A0 (en) 2011-07-31
CN103554030A (zh) 2014-02-05
CN102281877B (zh) 2014-07-23
EP2387400A1 (en) 2011-11-23
CA2749101A1 (en) 2010-07-22
CN102281877A (zh) 2011-12-14

Similar Documents

Publication Publication Date Title
JP2012515210A (ja) ベンダムスチン遊離塩基の新規の形態
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
US8884013B2 (en) Polymorphs of Dasatinib, preparation methods and pharmaceutical compositions thereof
HK1220966A1 (zh) 盐酸苯达莫司汀固体形式
AU2021277593A1 (en) Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate
US20160354351A1 (en) Solid state forms of vemurafenib hydrochloride
CN121889396A (zh) 用于治疗甲状腺眼病的林西替尼的结晶盐
US20250136610A1 (en) Crystalline forms of trilaciclib and trilaciclib salts
AU2017342239B2 (en) Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-N-methylpicolinamide
US12012421B2 (en) Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate
KR20230026384A (ko) 화합물의 결정 형태
US20240409501A1 (en) Cyrstalline forms of rip1 inhibitor
CN101228151B (zh) 4-甲基-n-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的盐
WO2026067446A1 (zh) 一种大稠环化合物的盐、多晶型物及其应用
WO2017029408A1 (en) Solid state forms of sofosbuvir
CA2944150A1 (en) Polymorphic forms and co-crystals of a c-met inhibitor
HK40088128A (en) Salt of compound and pharmaceutical composition containing salt
CN112142730A (zh) 杂芳基并四氢吡啶类化合物的固体形式及其制备方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141216